ConjuChem DM2 103
”A Randomized,Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients with Type 2 Diabetes Mellitus on Metformin Monotherapy”
| Protocol | |
|---|
| Identifier | DM200-103 |
|---|
| UID | f288c55d-9534-44c8-8f07-007d8564da60 |
|---|
| Status | Done - Archived |
|---|
| Phase | 2 |
|---|
| Category | Diabetes Type 2 |
|---|
| Launch Year | 2012 |
|---|
| NCT Number | - |
|---|
| Created | 2012-01-06 12:49 |
|---|
| Last Updated | 2012-01-06 12:49 |
|---|
Description
Key Elements: Study drug CJC-1134-PC is a GLP-1 analog similar to Byetta. There is a 1 in 5 chance of placebo Study drug administration: CJC-1134 PC or placebo treatment will be administered weekly by subcutaneous injection in the abdomen with patients in a fasting state. 23 Visits (1 Screening Visit, 18 Treatment Visits, 6 week follow-up period ) $50 per visit Body mass index of 27 to 45 kg/m2 HbA1c >7.0% and < 11% at Screening
Comment
No comment.
